Safety and Adverse Effects of Targeted Therapies
A special issue of Current Oncology (ISSN 1718-7729).
Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 325
Special Issue Editor
Special Issue Information
Dear Colleagues,
Advances in the knowledge of cancer molecular biology have led to the identification of oncogenic drivers and the development of targeted therapies. In just a few years, tyrosine kinase inhibitors (TKi) have become the standard of care for several solid cancers, including non-small cell lung cancer (NSCLC), melanoma and breast, renal and gastrointestinal neoplasms. Some agents have even obtained agnostic approval, regardless of the primary tumor. In addition, with the advent of new molecular diagnostics, such as next generation sequencing (NGS), we expect an increasing number of molecular drivers and further expansion of targeted therapies in clinical practice.
These therapies have shown advantages in terms of both efficacy and safety when compared with chemotherapy. However, many agents have common side effects, with a significant impact on patients' quality of life, such as skin toxicity and diarrhoea. Other agents have peculiar safety profiles that require careful management.
This Special Issue welcomes articles, reports and reviews on the "Safety and Adverse Effects of Targeted Therapies" and aims to explore areas of unmeet needs and research on clinical challenges.
Dr. Marco Russano
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- targeted therapy
- safety
- adverse effects
- tyrosine kinase inhibitor
- oncogenic driver
- molecular target
- toxicity
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
